Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone.
about
Towards Stratified Medicine in Plasma Cell MyelomaAnalysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD.A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: the Japanese MM-011 trialSafety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myelomaReal-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience.Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR.Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.Quantitative PCR: an alternative approach to detect common copy number alterations in multiple myeloma.How is patient care for multiple myeloma advancing?Pomalidomide in the management of relapsed multiple myeloma.Management of high-risk Myeloma: an evidence-based review of treatment strategies.Current Review on High-Risk Multiple Myeloma.Treatment of Relapsed/Refractory Multiple Myeloma.High-risk multiple myeloma: a multifaceted entity, multiple therapeutic challenges.Outcome of allogeneic transplantation in newly diagnosed and relapsed/refractory multiple myeloma: long-term follow-up in a single institution.Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testingPomalidomide in the treatment of multiple myeloma: design, development and place in therapy.Meta-analysis of the efficacy of treatments for newly diagnosed and relapsed/refractory multiple myeloma with del(17p).Insights on Genomic and Molecular Alterations in Multiple Myeloma and Their Incorporation towards Risk-Adapted Treatment Strategy: Concise Clinical Review.Comparative Efficacy of Daratumumab Monotherapy and Pomalidomide Plus Low-Dose Dexamethasone in the Treatment of Multiple Myeloma: A Matching Adjusted Indirect Comparison.Therapeutic monoclonal antibodies in combination with pomalidomide can overcome refractoriness to both agents in multiple myeloma: A case-based approach.Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results.Pomalidomide: A Review in Relapsed and Refractory Multiple Myeloma.Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASP
P2860
Q28074994-E87119C3-64E2-407E-A8E6-108FC0A553DFQ31119290-6E3D68AF-1E06-456A-8592-34189855DEA5Q33431621-1A3816BC-FC94-4F35-89A0-8BC82333A204Q33432492-4B836515-5EB0-4F23-B96E-60D67123BC20Q33439437-B9A110D2-67CB-44DB-8242-70CD701299B2Q33442923-CE23D78B-1B39-48E2-865A-9A645B0AC71EQ33785935-CA35CCB2-9951-42AD-B55C-A92FE4ED7F53Q37037265-A741A007-07BA-406C-9ED7-444C5D0F5CC8Q37228327-DCA81FCF-802B-41DC-AB33-149A9E157C6AQ38645307-94F288C5-AEC4-4DA9-B2AF-BE9B7E2EDEAFQ38786149-0312A13D-46D0-4E51-BA64-B24D13E3FD9CQ38855510-7526A4E9-5396-4CC8-AE8E-371E1C6A4531Q38874675-8A496DCF-97B7-4A05-A06A-5DE68FF91FEEQ38895167-88CB46CD-9980-478B-9359-E46ED5369E1AQ38970597-B156CFCF-1383-42B1-86B7-14DF4B103EA1Q38979403-1BAC701C-B209-402F-85ED-A06582B05016Q40827148-81907210-F981-4EA3-9A0C-160C4E4C98D1Q41346803-BFDD5479-D999-43D9-81C7-2B44D6977E65Q41545464-CFED62C6-DAC2-49D1-A995-8046D23F2554Q42365345-BE504731-F9E8-48A2-B135-6DB1FE70E107Q47095937-B01BDCB0-CE11-4ADA-BB6E-86F76BCAE980Q47344786-8C5E7F0C-DC8D-4A4D-A6C6-396CA47A92E4Q48176748-900D1958-A4BA-482A-8ED5-480DCF589030Q50050288-34AA5BE5-0377-411E-B201-34E1C9793B91Q50129476-E34077F3-4F44-4E78-98A9-93572DB088E2Q52609413-1F5034D9-0E6E-4E3E-B60C-C7AFE3ED9953
P2860
Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Cytogenetics and long-term sur ...... de and low-dose dexamethasone.
@ast
Cytogenetics and long-term sur ...... de and low-dose dexamethasone.
@en
type
label
Cytogenetics and long-term sur ...... de and low-dose dexamethasone.
@ast
Cytogenetics and long-term sur ...... de and low-dose dexamethasone.
@en
prefLabel
Cytogenetics and long-term sur ...... de and low-dose dexamethasone.
@ast
Cytogenetics and long-term sur ...... de and low-dose dexamethasone.
@en
P2093
P2860
P50
P1433
P1476
Cytogenetics and long-term sur ...... ide and low-dose dexamethasone
@en
P2093
Adrian Alegre
Andrew Spencer
Anne Banos
Christian Jacques
Christine Chen
Christoph Renner
Katja C Weisel
Kevin Hong
Kevin W Song
Lars Sternas
P2860
P304
P356
10.3324/HAEMATOL.2014.117077
P50
P577
2015-08-06T00:00:00Z